Immunotherapy in Lung Cancer

>

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Latest News

Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC

November 14th 2022

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma
Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma

June 14th 2022

Adjuvant Atezolizumab Approved in Europe for High-Risk NSCLC With PD-L1 of ≥50%
Adjuvant Atezolizumab Approved in Europe for High-Risk NSCLC With PD-L1 of ≥50%

June 14th 2022

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%
Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Tiragolumab Plus Atezolizumab/Chemo Misses PFS End Point in Extensive-Stage SCLC
Tiragolumab Plus Atezolizumab/Chemo Misses PFS End Point in Extensive-Stage SCLC

March 30th 2022

Video Series
Video Interviews
Podcasts

More News